Procedural data according to the cardiopathy type and to the ablation approach
| . | ICM (n = 121) . | NICM (n = 50) . | P-value . | Image-aided (n = 108) . | Image-guided (n = 63) . | P-value . | Total patients (n = 171) . |
|---|---|---|---|---|---|---|---|
| Procedure time (min) | 198 ± 78 | 178 ± 69 | 0.18 | 210 ± 69 | 159 ± 78 | < 0.001 | 192 ± 72 |
| Fluoroscopy time (min) | 16 ± 10 | 16 ± 10 | 0.67 | 18 ± 10 | 13 ± 9 | 0.003 | 16 ± 10 |
| RF time (min) | 19 ± 11 | 10 ± 7 | <0.001 | 18 ± 12 | 14 ± 9 | 0.01 | 17 ± 11 |
| Epicardial mapping | 30 (24.8) | 17 (34.0) | 0.26 | 34 (31.5) | 13 (20.6) | 0.3 | 47 (27.5) |
| Transeptal approach | 101 (83.5) | 20 (40.0) | <0.001 | 77 (71.3) | 44 (69.8) | 0.99 | 121 (70.8) |
| Multi-polar mapping catheter | 44 (36.4) | 7 (14.0) | 0.003 | 34 (31.5) | 17 (27.0) | 0.61 | 51 (29.8) |
| VT non-inducibility post-first ablation attempt | 88 (76.7) | 35 (70.0) | 0.71 | 69 (63.9) | 54 (85.7) | 0.002 | 123 (71.9) |
| MAEs | 7 (5.8) | 2 (4.0) | 0.99 | 4 (3.7) | 5 (7.9) | 0.81 | 9 (5.3) |
| Incomplete substrate elimination | 17 (14.0) | 7 (14.0) | 0.99 | 11 (10.2) | 13 (20.6) | 0.04 | 24 (14.0) |
| Acute procedural endpoints | 0.5 | 0.2 | |||||
| Acute procedural success | 87 (71.9) | 34 (68.0) | 72 (66.7) | 49 (77.8) | 121 (70.8) | ||
| Partial procedural success | 28 (23.1) | 11 (22.0) | 26 (24.1) | 13 (20.6) | 39 (22.8) | ||
| Unsuccessful | 6 (5.0) | 5 (10.0) | 10 (9.3) | 1 (1.6) | 11 (6.4) |
| . | ICM (n = 121) . | NICM (n = 50) . | P-value . | Image-aided (n = 108) . | Image-guided (n = 63) . | P-value . | Total patients (n = 171) . |
|---|---|---|---|---|---|---|---|
| Procedure time (min) | 198 ± 78 | 178 ± 69 | 0.18 | 210 ± 69 | 159 ± 78 | < 0.001 | 192 ± 72 |
| Fluoroscopy time (min) | 16 ± 10 | 16 ± 10 | 0.67 | 18 ± 10 | 13 ± 9 | 0.003 | 16 ± 10 |
| RF time (min) | 19 ± 11 | 10 ± 7 | <0.001 | 18 ± 12 | 14 ± 9 | 0.01 | 17 ± 11 |
| Epicardial mapping | 30 (24.8) | 17 (34.0) | 0.26 | 34 (31.5) | 13 (20.6) | 0.3 | 47 (27.5) |
| Transeptal approach | 101 (83.5) | 20 (40.0) | <0.001 | 77 (71.3) | 44 (69.8) | 0.99 | 121 (70.8) |
| Multi-polar mapping catheter | 44 (36.4) | 7 (14.0) | 0.003 | 34 (31.5) | 17 (27.0) | 0.61 | 51 (29.8) |
| VT non-inducibility post-first ablation attempt | 88 (76.7) | 35 (70.0) | 0.71 | 69 (63.9) | 54 (85.7) | 0.002 | 123 (71.9) |
| MAEs | 7 (5.8) | 2 (4.0) | 0.99 | 4 (3.7) | 5 (7.9) | 0.81 | 9 (5.3) |
| Incomplete substrate elimination | 17 (14.0) | 7 (14.0) | 0.99 | 11 (10.2) | 13 (20.6) | 0.04 | 24 (14.0) |
| Acute procedural endpoints | 0.5 | 0.2 | |||||
| Acute procedural success | 87 (71.9) | 34 (68.0) | 72 (66.7) | 49 (77.8) | 121 (70.8) | ||
| Partial procedural success | 28 (23.1) | 11 (22.0) | 26 (24.1) | 13 (20.6) | 39 (22.8) | ||
| Unsuccessful | 6 (5.0) | 5 (10.0) | 10 (9.3) | 1 (1.6) | 11 (6.4) |
Bold values indicate P-values related to statistically significant differences.
ICM, ischaemic cardiomyopathy; MAE, major adverse event; NICM, non-ischaemic cardiomyopathy; RF, radiofrequency; VT, ventricular tachycardia.
Procedural data according to the cardiopathy type and to the ablation approach
| . | ICM (n = 121) . | NICM (n = 50) . | P-value . | Image-aided (n = 108) . | Image-guided (n = 63) . | P-value . | Total patients (n = 171) . |
|---|---|---|---|---|---|---|---|
| Procedure time (min) | 198 ± 78 | 178 ± 69 | 0.18 | 210 ± 69 | 159 ± 78 | < 0.001 | 192 ± 72 |
| Fluoroscopy time (min) | 16 ± 10 | 16 ± 10 | 0.67 | 18 ± 10 | 13 ± 9 | 0.003 | 16 ± 10 |
| RF time (min) | 19 ± 11 | 10 ± 7 | <0.001 | 18 ± 12 | 14 ± 9 | 0.01 | 17 ± 11 |
| Epicardial mapping | 30 (24.8) | 17 (34.0) | 0.26 | 34 (31.5) | 13 (20.6) | 0.3 | 47 (27.5) |
| Transeptal approach | 101 (83.5) | 20 (40.0) | <0.001 | 77 (71.3) | 44 (69.8) | 0.99 | 121 (70.8) |
| Multi-polar mapping catheter | 44 (36.4) | 7 (14.0) | 0.003 | 34 (31.5) | 17 (27.0) | 0.61 | 51 (29.8) |
| VT non-inducibility post-first ablation attempt | 88 (76.7) | 35 (70.0) | 0.71 | 69 (63.9) | 54 (85.7) | 0.002 | 123 (71.9) |
| MAEs | 7 (5.8) | 2 (4.0) | 0.99 | 4 (3.7) | 5 (7.9) | 0.81 | 9 (5.3) |
| Incomplete substrate elimination | 17 (14.0) | 7 (14.0) | 0.99 | 11 (10.2) | 13 (20.6) | 0.04 | 24 (14.0) |
| Acute procedural endpoints | 0.5 | 0.2 | |||||
| Acute procedural success | 87 (71.9) | 34 (68.0) | 72 (66.7) | 49 (77.8) | 121 (70.8) | ||
| Partial procedural success | 28 (23.1) | 11 (22.0) | 26 (24.1) | 13 (20.6) | 39 (22.8) | ||
| Unsuccessful | 6 (5.0) | 5 (10.0) | 10 (9.3) | 1 (1.6) | 11 (6.4) |
| . | ICM (n = 121) . | NICM (n = 50) . | P-value . | Image-aided (n = 108) . | Image-guided (n = 63) . | P-value . | Total patients (n = 171) . |
|---|---|---|---|---|---|---|---|
| Procedure time (min) | 198 ± 78 | 178 ± 69 | 0.18 | 210 ± 69 | 159 ± 78 | < 0.001 | 192 ± 72 |
| Fluoroscopy time (min) | 16 ± 10 | 16 ± 10 | 0.67 | 18 ± 10 | 13 ± 9 | 0.003 | 16 ± 10 |
| RF time (min) | 19 ± 11 | 10 ± 7 | <0.001 | 18 ± 12 | 14 ± 9 | 0.01 | 17 ± 11 |
| Epicardial mapping | 30 (24.8) | 17 (34.0) | 0.26 | 34 (31.5) | 13 (20.6) | 0.3 | 47 (27.5) |
| Transeptal approach | 101 (83.5) | 20 (40.0) | <0.001 | 77 (71.3) | 44 (69.8) | 0.99 | 121 (70.8) |
| Multi-polar mapping catheter | 44 (36.4) | 7 (14.0) | 0.003 | 34 (31.5) | 17 (27.0) | 0.61 | 51 (29.8) |
| VT non-inducibility post-first ablation attempt | 88 (76.7) | 35 (70.0) | 0.71 | 69 (63.9) | 54 (85.7) | 0.002 | 123 (71.9) |
| MAEs | 7 (5.8) | 2 (4.0) | 0.99 | 4 (3.7) | 5 (7.9) | 0.81 | 9 (5.3) |
| Incomplete substrate elimination | 17 (14.0) | 7 (14.0) | 0.99 | 11 (10.2) | 13 (20.6) | 0.04 | 24 (14.0) |
| Acute procedural endpoints | 0.5 | 0.2 | |||||
| Acute procedural success | 87 (71.9) | 34 (68.0) | 72 (66.7) | 49 (77.8) | 121 (70.8) | ||
| Partial procedural success | 28 (23.1) | 11 (22.0) | 26 (24.1) | 13 (20.6) | 39 (22.8) | ||
| Unsuccessful | 6 (5.0) | 5 (10.0) | 10 (9.3) | 1 (1.6) | 11 (6.4) |
Bold values indicate P-values related to statistically significant differences.
ICM, ischaemic cardiomyopathy; MAE, major adverse event; NICM, non-ischaemic cardiomyopathy; RF, radiofrequency; VT, ventricular tachycardia.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
